{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:59:10Z","timestamp":1761919150897},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s11910-008-0066-2","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T16:00:50Z","timestamp":1224086450000},"page":"427-433","source":"Crossref","is-referenced-by-count":48,"title":["Neuromyelitis optica: Diagnosis, pathogenesis, and treatment"],"prefix":"10.1007","volume":"8","author":[{"given":"Bruce","family":"Cree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"66_CR1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"V.A. Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106\u20132112.","journal-title":"Lancet"},{"key":"66_CR2","first-page":"409","volume":"17","author":"P. Agre","year":"1996","unstructured":"Agre P, Nielsen S: The aquaporin family of water channels in kidney. Nephrologie 1996, 17:409\u2013415.","journal-title":"Nephrologie"},{"key":"66_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tins.2007.11.003","volume":"31","author":"M.J. Tait","year":"2008","unstructured":"Tait MJ, Saadoun S, Bell BA, et al.: Water movements in the brain: role of aquaporins. Trends Neurosci 2008, 31:37\u201343.","journal-title":"Trends Neurosci"},{"key":"66_CR4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.neuroscience.2004.08.049","volume":"129","author":"M. Amiry-Moghaddam","year":"2004","unstructured":"Amiry-Moghaddam M, Frydenlund DS, Ottersen OP: Anchoring of aquaporin-4 in brain: molecular mechanisms and implications for the physiology and pathophysiology of water transport. Neuroscience 2004, 129:999\u20131010.","journal-title":"Neuroscience"},{"key":"66_CR5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"V.A. Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473\u2013477.","journal-title":"J Exp Med"},{"key":"66_CR6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1620\/tjem.210.307","volume":"210","author":"T. Takahashi","year":"2006","unstructured":"Takahashi T, Fujihara K, Nakashima I, et al.: Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006, 210:307\u2013313.","journal-title":"Tohoku J Exp Med"},{"key":"66_CR7","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1371\/journal.pmed.0040133","volume":"4","author":"F. Paul","year":"2007","unstructured":"Paul F, Jarius S, Aktas O, et al.: Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007, 4:e133","journal-title":"PLoS Med"},{"key":"66_CR8","doi-asserted-by":"crossref","unstructured":"Marignier R, De Seze J, Vukusic S, et al.: NMO-IgG and Devic\u2019s neuromyelitis optica: a French experience. Mult Scler 2008 (in press).","DOI":"10.1177\/1352458507084595"},{"key":"66_CR9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-2002-36534","volume":"22","author":"B.A. Cree","year":"2002","unstructured":"Cree BA, Goodin DS, Hauser SL: Neuromyelitis optica. Semin Neurol 2002, 22:105\u2013122.","journal-title":"Semin Neurol"},{"key":"66_CR10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"D.M. Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, et al.: The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 1999, 53:1107\u20131114.","journal-title":"Neurology"},{"key":"66_CR11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"D.M. Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, et al.: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485\u20131489.","journal-title":"Neurology"},{"key":"66_CR12","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00415-007-0509-8","volume":"254","author":"A. Saiz","year":"2007","unstructured":"Saiz A, Zuliani L, Blanco Y, et al.: Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 2007, 254:1233\u20131237.","journal-title":"J Neurol"},{"key":"66_CR13","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"B.G. Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566\u2013569.","journal-title":"Ann Neurol"},{"key":"66_CR14","doi-asserted-by":"crossref","unstructured":"Mateillo M, Lennon VA, Jacob A, et al.: NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008 (in press).","DOI":"10.1212\/01.wnl.0000303817.82134.da"},{"key":"66_CR15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archopht.126.4.566","volume":"126","author":"M.J. Dinkin","year":"2008","unstructured":"Dinkin MJ, Cestari DM, Stein MC, et al.: NMO antibody-positive recurrent optic neuritis without clear evidence of transverse myelitis. Arch Ophthalmol 2008, 126:566\u2013570.","journal-title":"Arch Ophthalmol"},{"key":"66_CR16","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T. Takahashi","year":"2007","unstructured":"Takahashi T, Fujiara K, Nakashima I, et al.: Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130:1235\u20131243.","journal-title":"Brain"},{"key":"66_CR17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1620\/tjem.209.269","volume":"209","author":"T. Misu","year":"2006","unstructured":"Misu T, Fujihara K, Nakamura M, et al.: Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 2006, 209:269\u2013275.","journal-title":"Tohoku J Exp Med"},{"key":"66_CR18","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"C.F. Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, et al.: A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 2002, 125:1450\u20131461.","journal-title":"Brain"},{"key":"66_CR19","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"S.F. Roemer","year":"2007","unstructured":"Roemer SF, Parisi JE, Lennon VA, et al.: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194\u20131205.","journal-title":"Brain"},{"key":"66_CR20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","volume":"65","author":"T. Misu","year":"2005","unstructured":"Misu T, Fujihara K, Nakashima I, et al.: Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005, 65:1479\u20131482.","journal-title":"Neurology"},{"key":"66_CR21","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","volume":"130","author":"T. Misu","year":"2007","unstructured":"Misu T, Fujihara K, Kakita A, et al.: Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224\u20131234.","journal-title":"Brain"},{"key":"66_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00401-006-0169-2","volume":"113","author":"C. Sinclair","year":"2007","unstructured":"Sinclair C, Kirk J, Herron B, et al.: Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol 2007, 113:187\u2013194.","journal-title":"Acta Neuropathol"},{"key":"66_CR23","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"S.R. Hinson","year":"2007","unstructured":"Hinson SR, Pittock SJ, Lucchinetti CF, et al.: Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221\u20132231.","journal-title":"Neurology"},{"key":"66_CR24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mcn.2006.09.008","volume":"34","author":"X.N. Zeng","year":"2007","unstructured":"Zeng XN, Sun XL, Gao L, et al.: Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes. Mol Cell Neurosci 2007, 34:34\u201339.","journal-title":"Mol Cell Neurosci"},{"key":"66_CR25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","volume":"63","author":"S.J. Pittock","year":"2006","unstructured":"Pittock SJ, Lennon VA, Krecke K, et al.: Brain abnormalities in neuromyelitis optica. Arch Neurol 2006, 63:390\u2013396.","journal-title":"Arch Neurol"},{"key":"66_CR26","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","volume":"63","author":"S.J. Pittock","year":"2006","unstructured":"Pittock SJ, Weinshenker BG, Lucchinetti CF, et al.: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964\u2013968.","journal-title":"Arch Neurol"},{"key":"66_CR27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0022-510X(91)90094-N","volume":"102","author":"J. Kira","year":"1991","unstructured":"Kira J, Harada M, Yamaguchi Y, et al.: Hyperprolactinemia in multiple sclerosis. J Neurol Sci 1991, 102:61\u201366.","journal-title":"J Neurol Sci"},{"key":"66_CR28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1212\/WNL.48.1.58","volume":"48","author":"J.C. Vernant","year":"1997","unstructured":"Vernant JC, Cabre P, Smadja D, et al.: Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology 1997, 48:58\u201364.","journal-title":"Neurology"},{"key":"66_CR29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2169\/internalmedicine.39.296","volume":"39","author":"K. Yamasaki","year":"2000","unstructured":"Yamasaki K, Horiuchi I, Minohara M, et al.: Hyperprolactinemia in optico-spinal multiple sclerosis. Intern Med 2000, 39:296\u2013299.","journal-title":"Intern Med"},{"key":"66_CR30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1191\/1352458505ms1200cr","volume":"11","author":"A.Y. Poppe","year":"2005","unstructured":"Poppe AY, Lapierre Y, Melancon D, et al.: Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005, 11:617\u2013621.","journal-title":"Mult Scler"},{"key":"66_CR31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/1352458507082617","volume":"14","author":"J. Cabrera-Gomez","year":"2008","unstructured":"Cabrera-Gomez J, Saiz-Hinarejos A, Graus F, et al.: Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Mult Scler 2008, 14:248\u2013251.","journal-title":"Mult Scler"},{"key":"66_CR32","unstructured":"Levy M, Jones M, Kerr D: The role of anti-aquaporin-4 antibodies in the pathogenesis of neuromyelitis opica [abstract P04.061]. Paper presented at the 59th American Academy of Neurology Annual Meeting. Boston, MA. April 28 to May 5, 2007."},{"key":"66_CR33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1212\/01.wnl.0000223346.09426.34","volume":"67","author":"P.H. Lalive","year":"2006","unstructured":"Lalive PH, Menge T, Barman I, et al.: Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology 2006, 67:176\u2013177.","journal-title":"Neurology"},{"key":"66_CR34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"B.G. Weinshenker","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878\u2013886.","journal-title":"Ann Neurol"},{"key":"66_CR35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","volume":"58","author":"M. Keegan","year":"2002","unstructured":"Keegan M, Pineda AA, McClelland RL, et al.: Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143\u2013146.","journal-title":"Neurology"},{"key":"66_CR36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","volume":"13","author":"S. Watanabe","year":"2007","unstructured":"Watanabe S, Naashima I, Misu T, et al.: Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007, 13:128\u2013132.","journal-title":"Mult Scler"},{"key":"66_CR37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1537-2995.1985.25185116504.x","volume":"25","author":"A.J. Aguilera","year":"1985","unstructured":"Aguilera AJ, Carlow TJ, Smith KJ, et al.: Lymphocytaplasmapheresis in Devic\u2019s syndrome. Transfusion 1985, 25:54\u201356.","journal-title":"Transfusion"},{"key":"66_CR38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/jnnp.2005.086306","volume":"77","author":"I. Nozaki","year":"2006","unstructured":"Nozaki I, Hamaguchi T, Komai K, et al.: Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry 2006, 77:1094\u20131095.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"66_CR39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68","author":"D.M. Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al.: A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007, 68:603\u2013605.","journal-title":"Neurology"},{"key":"66_CR40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","volume":"13","author":"C. Papeix","year":"2007","unstructured":"Papeix C, Vidal JS, De Seze J, et al.: Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007, 13:256\u2013259.","journal-title":"Mult Scler"},{"key":"66_CR41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","volume":"252","author":"Y. Warabi","year":"2007","unstructured":"Warabi Y, Matsumoto Y, Hayashi H: Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007, 252:57\u201361.","journal-title":"J Neurol Sci"},{"key":"66_CR42","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"R.N. Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE: Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219\u20131220.","journal-title":"Neurology"},{"key":"66_CR43","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"B.A. Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, et al.: An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270\u20131272.","journal-title":"Neurology"},{"key":"66_CR44","unstructured":"Jacobs A, Weinshenker B, McKinskey N, et al.: Retrospective analysis of rituximab treatment of 26 cases of neuromyelitis optica [abstract S32.002]. Paper presented at the 59th American Academy of Neurology Annual Meeting. Boston, MA. April 28 to May 5, 2007."},{"key":"66_CR45","unstructured":"Genain C, Kornyeyva E, Ross M, et al.: An open label clinical trial of rituximab in neuromyeltis optica [abstract S52.004]. Paper presented at the 59th American Academy of Neurology Annual Meeting. Boston, MA. April 28 to May 5, 2007."},{"key":"66_CR46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","volume":"28","author":"M. Capobinaco","year":"2007","unstructured":"Capobinaco M, Malucchi S, Di Sapio A, et al.: Variable responses to rituximab treatment in neuromyelitis optica (Devic\u2019s disease). Neurol Sci 2007, 28:209\u2013211.","journal-title":"Neurol Sci"},{"key":"66_CR47","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","volume":"63","author":"B. Weinstock-Guttman","year":"2006","unstructured":"Weinstock-Guttman B, Ramanathan M, Lincoff N, et al.: Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006, 63:957\u2013963.","journal-title":"Arch Neurol"},{"key":"66_CR48","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","volume":"13","author":"S. Watanabe","year":"2007","unstructured":"Watanabe S, Misu T, Miyazama I, et al.: Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007, 13:968\u2013974.","journal-title":"Mult Scler"},{"key":"66_CR49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","volume":"31","author":"J. Bakker","year":"2004","unstructured":"Bakker J, Metz L: Devic\u2019s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265\u2013267.","journal-title":"Can J Neurol Sci"},{"key":"66_CR50","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","volume":"46","author":"K. Okada","year":"2007","unstructured":"Okada K, Tsuji S, Tanaka K: Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 2007, 46:1671\u20131672.","journal-title":"Intern Med"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-008-0066-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-008-0066-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-008-0066-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:24:40Z","timestamp":1559435080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-008-0066-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1007\/s11910-008-0066-2","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}